Ojewola R W, Tijani K H, Jeje E A, Anunobi C C, Ogunjimi M A, Ezenwa E V, Ogundiniyi O S
Department of Surgery, Lagos University Teaching Hospital, Lagos, Nigeria.
Niger J Clin Pract. 2012 Jul-Sep;15(3):315-9. doi: 10.4103/1119-3077.100630.
To determine the significance of an extended 10-core transrectal biopsy protocol in different categories of patients with suspected prostate cancer using digital guidance.
We studied 125 men who were being evaluated for prostate cancer. They all had an extended 10-core digitally guided transrectal prostatic biopsy done for either an elevated serum prostate-specific antigen (PSA) or an abnormal digital rectal examination finding or both. Sextant biopsy samples were collected first, followed by additional four lateral biopsies in all patients. Both groups of specimens were analyzed separately. The cancer detection rates of both sextant and extended 10-core biopsy protocols at different PSA levels and digital rectal examination (DRE) findings were determined and compared. The level of significance of difference in cancer detection was determined using Pearson's Chi square test with level of significance set at <0.05.
The overall cancer detection by the extended technique was 61 (48.8%) cases while the sextant protocol detected cancer in 52 cases. The 10-core extended protocol yielded an increase in cancer detection rate of 14.8% but the improvement in detection rate was only statistically significant in the sub-set of patients with PSA between 4.1 and 10 ng/mL, with or without abnormality on DRE, with an overall increase detection rate of 33%.(P=0.04)
Our study has shown that a 10-core prostate biopsy protocol significantly improves cancer detection in patients with suspected early cancer. It should therefore be the optimum biopsy protocol for patients with gray-zone PSA value, with or without abnormal DRE.
使用数字引导确定扩展的10针经直肠活检方案在不同类别疑似前列腺癌患者中的意义。
我们研究了125名接受前列腺癌评估的男性。他们均因血清前列腺特异性抗原(PSA)升高或直肠指检异常或两者兼有,接受了扩展的10针数字引导经直肠前列腺活检。首先采集六分区活检样本,随后对所有患者额外进行4针外侧活检。两组样本分别进行分析。确定并比较六分区活检和扩展的10针活检方案在不同PSA水平和直肠指检(DRE)结果时的癌症检出率。使用Pearson卡方检验确定癌症检出差异的显著性水平,显著性水平设定为<0.05。
扩展技术的总体癌症检出率为61例(48.8%),而六分区活检方案检出癌症52例。10针扩展方案使癌症检出率提高了14.8%,但仅在PSA为4.1至10 ng/mL的患者亚组中,无论DRE是否异常,检出率的提高在统计学上具有显著性,总体检出率提高了33%。(P = 0.04)
我们的研究表明,10针前列腺活检方案显著提高了疑似早期癌症患者的癌症检出率。因此,对于PSA处于灰色区域值且无论DRE是否异常的患者,它应是最佳的活检方案。